Marc A. Cohen
Net Worth
Last updated:
What is Marc A. Cohen net worth?
The estimated net worth of Mr. Marc A. Cohen is at least $361,282 as of 18 Feb 2021. He owns shares worth $13,782 as insider and has received compensation worth at least $347,500 in C4 Therapeutics, Inc..
What is the salary of Marc A. Cohen?
Mr. Marc A. Cohen salary is $69,500 per year as Co-Founder, Executive Chairman & Sec. in C4 Therapeutics, Inc..
How old is Marc A. Cohen?
Mr. Marc A. Cohen is 62 years old, born in 1963.
What stocks does Marc A. Cohen currently own?
As insider, Mr. Marc A. Cohen owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | Co-Founder, Executive Chairman & Sec. | 5,030 | $2.74 | $13,782 |
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Marc A. Cohen insider trading
C4 Therapeutics key executives
C4 Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Adam S. Crystal M.D., Ph.D. (48) Chief Medical Officer
- Dr. Kenneth C. Anderson M.D., Ph.D. (74) Co-Founder, Independent Director & Member of Scientific Advisory Board
- Mr. Andrew J. Hirsch (54) Chief Executive Officer, Pres & Director
- Mr. Marc A. Cohen (62) Co-Founder, Executive Chairman & Sec.